S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.54 (-2.30%)
AMD   100.08 (-3.09%)
T   14.78 (+0.75%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-7.30%)
GE   107.76 (-0.95%)
DIS   79.54 (-2.61%)
AMC   7.85 (-3.68%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.54 (-2.30%)
AMD   100.08 (-3.09%)
T   14.78 (+0.75%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-7.30%)
GE   107.76 (-0.95%)
DIS   79.54 (-2.61%)
AMC   7.85 (-3.68%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.54 (-2.30%)
AMD   100.08 (-3.09%)
T   14.78 (+0.75%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-7.30%)
GE   107.76 (-0.95%)
DIS   79.54 (-2.61%)
AMC   7.85 (-3.68%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.54 (-2.30%)
AMD   100.08 (-3.09%)
T   14.78 (+0.75%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-7.30%)
GE   107.76 (-0.95%)
DIS   79.54 (-2.61%)
AMC   7.85 (-3.68%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
Positive News SentimentPositive News
NASDAQ:OCS

Oculis (OCS) Stock Forecast, Price & News

$11.34
-0.41 (-3.49%)
(As of 03:58 PM ET)
Compare
Today's Range
$11.25
▼
$11.40
50-Day Range
$11.00
▼
$14.00
52-Week Range
$6.26
▼
$14.50
Volume
2,304 shs
Average Volume
20,997 shs
Market Capitalization
$412.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.40
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Oculis MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
196.9% Upside
$33.40 Price Target
Short Interest
Healthy
0.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.71) to ($1.40) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

749th out of 976 stocks

Pharmaceutical Preparations Industry

351st out of 447 stocks

See Top Rated MarketRank™ Stocks Here

OCS stock logo

About Oculis (NASDAQ:OCS) Stock

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

OCS Price History

OCS Stock News Headlines

September 25, 2023 | americanbankingnews.com
Analysts Set Oculis Holding AG (NASDAQ:OCS) PT at $33.40
September 24, 2023 | barrons.com
Oculis Holding AG Wt
October 3, 2023 | Legacy Research (Ad)
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)
“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”
September 14, 2023 | investing.com
Oculis Holding AG (OCS)
September 11, 2023 | finance.yahoo.com
Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase
August 30, 2023 | msn.com
B of A Securities Maintains Oculis Holding (OCS) Buy Recommendation
August 30, 2023 | markets.businessinsider.com
Expert Ratings for Oculis Holding
August 30, 2023 | finance.yahoo.com
Oculis to Present at Upcoming September Investor Conferences
October 3, 2023 | Chaikin Analytics (Ad)
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
August 29, 2023 | finanznachrichten.de
Oculis Holding AG: Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update
August 29, 2023 | finance.yahoo.com
Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update
August 17, 2023 | msn.com
Oculis: Swiss Pharma With Excellent Data, Unclear Fundamentals
August 8, 2023 | finance.yahoo.com
OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery
August 4, 2023 | msn.com
HC Wainwright & Co. Reiterates Oculis Holding (OCS) Buy Recommendation
August 3, 2023 | msn.com
Oculis enrols first patient in trial of its OCS-01 eye drops
August 2, 2023 | finance.yahoo.com
First Patient Enrolled in LEOPARD, an Investigator-Initiated Trial, with OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema
July 27, 2023 | finance.yahoo.com
Oculis Announces to Present at Upcoming August Investor Conferences
July 19, 2023 | finance.yahoo.com
Oculis to Present at OIS Retina Innovation Summit
July 14, 2023 | markets.businessinsider.com
Robert W. Baird Reaffirms Their Buy Rating on Oculis Holding (OCS)
June 15, 2023 | benzinga.com
Oculis Announces Partial Exercise of Underwriters' Option to Purchase Additional Ordinary Shares
June 15, 2023 | msn.com
BofA starts Oculis at buy rating, bullish on lead eye drug OCS-01
June 15, 2023 | finance.yahoo.com
Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics
June 15, 2023 | finance.yahoo.com
Oculis Announces Partial Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares
June 8, 2023 | markets.businessinsider.com
Wedbush Sticks to Its Buy Rating for Oculis Holding (OCS)
See More Headlines
Receive OCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oculis and its competitors with MarketBeat's FREE daily newsletter.

OCS Company Calendar

Last Earnings
8/29/2023
Today
10/03/2023
Next Earnings (Estimated)
12/05/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OCS
CUSIP
N/A
CIK
1953530
Web
www.oculis.com
Phone
41-21-711-3970
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$33.40
High Stock Price Forecast
$64.00
Low Stock Price Forecast
$23.00
Forecasted Upside/Downside
+184.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.22
Quick Ratio
7.22

Sales & Book Value

Annual Sales
$960,000.00
Price / Sales
445.40
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
36,390,000
Free Float
N/A
Market Cap
$427.58 million
Optionable
Not Optionable
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Riad Sherif M.B.A. (Age 55)
    M.D., CEO & Director
  • Ms. Sylvia Cheung (Age 48)
    Chief Financial Officer
  • Mr. Weibo Ding (Age 52)
    Global COO & GM of China
  • Dr. Bastian Dehmel (Age 52)
    Chief Devel. Officer & Head of Devel.
  • Dr. Joanne Chang M.D. (Age 62)
    Ph.D., Head of Medical Affairs & Chief Medical Officer
  • Mr. Páll Ragnar Jóhannesson (Age 42)
    Chief Strategy Officer
  • Dr. Fang Li
    Sr. VP of Regulatory Affairs

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













OCS Stock - Frequently Asked Questions

Should I buy or sell Oculis stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oculis in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OCS shares.
View OCS analyst ratings or view top-rated stocks.

What is Oculis' stock price forecast for 2023?

7 equities research analysts have issued 12 month price objectives for Oculis' stock. Their OCS share price forecasts range from $23.00 to $64.00. On average, they expect the company's stock price to reach $33.40 in the next twelve months. This suggests a possible upside of 184.3% from the stock's current price.
View analysts price targets for OCS or view top-rated stocks among Wall Street analysts.

How have OCS shares performed in 2023?

Oculis' stock was trading at $9.2122 at the start of the year. Since then, OCS stock has increased by 27.5% and is now trading at $11.75.
View the best growth stocks for 2023 here.

When is Oculis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, December 5th 2023.
View our OCS earnings forecast.

How were Oculis' earnings last quarter?

Oculis Holding AG (NASDAQ:OCS) posted its quarterly earnings data on Tuesday, August, 29th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by $0.09. The firm had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.28 million.

What is Oculis' stock symbol?

Oculis trades on the NASDAQ under the ticker symbol "OCS."

How do I buy shares of Oculis?

Shares of OCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oculis' stock price today?

One share of OCS stock can currently be purchased for approximately $11.75.

How much money does Oculis make?

Oculis (NASDAQ:OCS) has a market capitalization of $427.58 million and generates $960,000.00 in revenue each year.

How can I contact Oculis?

The official website for the company is www.oculis.com. The company can be reached via phone at 41-21-711-3970 or via email at ir@oculis.com.

This page (NASDAQ:OCS) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -